The material in this article has been gathered from the first stage (T1) of a
longitudinal study that considered the psycho-social issues associated
with the treatment of pediatric ALL and associated hematological disorders
including AML and the lymphomas. The Royal Children’s Hospital
Foundation and the Financial Markets Foundation for Children jointly
funded the study.